Edition:
India

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

313.97USD
17 Nov 2017
Change (% chg)

$-0.01 (-0.00%)
Prev Close
$313.98
Open
$313.47
Day's High
$315.86
Day's Low
$310.25
Volume
314,424
Avg. Vol
492,828
52-wk High
$348.65
52-wk Low
$244.31

Latest Key Developments (Source: Significant Developments)

Acorda announces royalty monetization transactions for $53 mln
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Acorda Therapeutics Inc :Acorda announces royalty monetization transactions for $53 million.Acorda Therapeutics - A $40 million royalty monetization with healthcare royalty partners and a $13 million royalty monetization with H. Lundbeck A/S​.Acorda Therapeutics Inc - ‍ In return for payment to Acorda, HCR obtains right to receive royalty revenue on Fampyra payable by Biogen.Acorda - ‍H. Lundbeck, Acorda amended license agreement for selincro to eliminate future royalty, milestone obligations on sale of Selincro outside U.S..Acorda Therapeutics Inc - Transaction does not include potential future milestones to be paid by Biogen​.  Full Article

Biogen presents new data from long-term extension of phase 1B study
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Biogen Inc ::Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab.Biogen Inc - ‍as of October 2017, Biogen and Eisai entered into a global collaboration agreement to jointly develop and commercialize aducanumab​.Biogen Inc - ‍results are consistent with previously reported analyses from phase 1B study​.  Full Article

Biogen Q3 earnings per share $5.79
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Biogen Inc ::Biogen reports quarterly revenues of $3.1 billion.Q3 revenue $3.1 billion versus I/B/E/S view $3.04 billion.Biogen Inc - ‍company restructures collaboration arrangements with eisai and neurimmune to improve long-term value of aducanumab​.Biogen qtrly ‍ non-gaap diluted eps $ 6.31​.Q3 earnings per share $5.79.Biogen - qtrly tecfidera revenue of ‍$ 1,070​ million versus. $1,034 million.Biogen - qtrly plegridy revenue of $‍​124 million versus $128 million last year.Biogen - qtrly avonex revenue of $‍538​ million versus. $580 million.Biogen - qtrly tysabri revenue of $‍​469 million versus $515 million last year.Biogen - qtrly spinraza revenue of $‍271​ million versus. $203 million in q2.Q3 earnings per share view $5.73 -- Thomson Reuters I/B/E/S.  Full Article

Biogen increases profit potential on investigational Alzheimer’S disease treatment
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Biogen Inc :Biogen increases profit potential on investigational Alzheimer’S disease treatment Aducanumab through amended agreement with Neurimmune Holding AG.Makes a one-time $150 million payment to Neurimmune in exchange for a 15 percent reduction in previously negotiated royalty rates​.‍Biogen licensed worldwide rights to Aducanumab from Neurimmune in 2007​.‍Also has an option to further reduce royalty owed on potential commercial sales of Aducanumab by an additional 5 percent.Option to reduce royalty owed on potential sales of Aducanumab by 5 percent is in exchange for additional one-time $50 million payment to Neurimmune.  Full Article

Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Biogen Inc :Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab.Biogen Inc - ‍Eisai has exercised its option to jointly develop and commercialize aducanumab, with Biogen continuing as development lead​.Biogen Inc - Co, Eisai to co-promote co's multiple sclerosis treatments, avonex , tysabri, tecfidera in Japan to accounts that co does not call upon​.Biogen Inc - ‍Neither party is making any upfront payments associated with exercise of aducanumab option​.Biogen Inc - ‍Under terms of agreement co will receive 55 percent of potential profits in United States and 68.5 percent of potential profits in Europe​.Biogen Inc - ‍Eisai's, Biogen's respective milestone payments under original agreement for aducanumab and BAN2401, have been eliminated​.Biogen Inc - ‍ Companies will continue to jointly develop elenbecestat (e2609), a beta amyloid cleaving enzyme (bace) inhibitor, and BAN2401​.Biogen Inc - ‍Financial terms for elenbecestat and ban2401 remain unchanged, other than eliminated BAN2401 milestone payments​.Biogen - Co to continue to lead phase 3 development of aducanumab, remain solely responsible for development costs for aducanumab until April 2018​.Biogen Inc - ‍ Under terms of agreement Eisai will receive 80 percent of potential profits in Japan and Asia excluding China and South Korea​.  Full Article

IONIS PHARMACEUTICALS INITIATES IONIS-MAPT RX STUDY IN PATIENTS WITH ALZHEIMER'S DISEASE
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS PHARMACEUTICALS INITIATES CLINICAL STUDY OF IONIS-MAPT RX IN PATIENTS WITH ALZHEIMER'S DISEASE.IONIS PHARMACEUTICALS INC - ‍IONIS EARNS $10 MILLION MILESTONE PAYMENT FROM BIOGEN​.  Full Article

Imraldi, Biogen's Adalimumab Biosimilar referencing Humira, is approved in EU
Friday, 25 Aug 2017 

Aug 24 (Reuters) - Biogen Inc :Imraldi(®), Biogen's Adalimumab Biosimilar referencing Humira(®), is approved in European Union.European commission granted a marketing authorization for Imraldi, an Adalimumab Biosimilar referencing H.umira.  Full Article

Forward Pharma receives $1.25 bln pursuant to settlement and license agreement with Biogen
Thursday, 9 Feb 2017 

Forward Pharma A/S - : Forward Pharma received US$ 1.25 bln pursuant to settlement and license agreement with Biogen .Forward Pharma A/S - received non-refundable cash fee of US$1.25 billion in connection with settlement and license agreement with two units of Biogen.  Full Article

Biogen's regulatory applications for nusinersen as a treatment for spinal muscular atrophy accepted by FDA, EMA
Friday, 28 Oct 2016 

Biogen Inc : Biogen's regulatory applications for nusinersen as a treatment for spinal muscular atrophy accepted by FDA and EMA . Biogen's regulatory applications for nusinersen as a treatment for spinal muscular atrophy accepted by FDA and EMA . Says nusinersen granted priority review by FDA . Biogen Inc - EMA plans to follow accelerated assessment timeline for nusinersen . Biogen Inc - Biogen exercised its option to worldwide rights to nusinersen in august 2016 . Says intends to market nusinersen under brand name spinraza .Says is initiating regulatory filings in other countries in coming months.  Full Article

Anavex signs material transfer agreement with Biogen
Wednesday, 28 Sep 2016 

Anavex Life Sciences :Signed material transfer agreement with Biogen under which Biogen will test Anavex's lead drug candidate, Anavex 2-73.  Full Article

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million